SecBot SecBot
PRESS-RELEASE ·Filed May 14, 2026

BIIB

Biogen Inc.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

The acquisition transforms Biogen's near-term growth profile with two approved products and a pipeline catalyst in nephrology. Monitor Q2 2026 earnings for updated financial guidance incorporating Apellis, and track SYFOVRE sales trajectory for CVR payout potential. The deal removes Apellis overhang and provides a clear revenue growth driver beyond Biogen's legacy neurology franchise.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$191.26
T+0 close · May 14, 2026 · via day close
Latest settled
+8.15%
T+60 · $206.85
Vs SPY
+4.83%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $191.26entry
  2. T+1 · 6mo ago +0.55%α +1.78% · $192.32
  3. T+5 · 6mo ago −1.23%α −0.52% · $188.90
  4. T+20 · 5mo ago +4.60%α +5.46% · $200.05
  5. T+60 · 3mo ago +8.15%α +4.83% · $206.85

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Biogen completed its acquisition of Apellis Pharmaceuticals for $41 per share in cash plus up to $4 per share in contingent value rights, adding two commercial products (EMPAVELI and SYFOVRE) that generated $689 million in combined 2025 net product revenue. The deal is expected to be accretive to Biogen's non-GAAP EPS in 2027 and materially increase its non-GAAP EPS CAGR through the end of the decade, while expanding Biogen into nephrology ahead of a key Phase 3 readout for felzartamab in 2027.

Key Financial Metrics

Revenue
$689.0M
Deal Value
$4.3B

Key Facts

  • Biogen acquired Apellis for $41 per share in cash plus up to $4 per share in CVRs tied to SYFOVRE sales thresholds.
  • Approximately 105.7 million shares (82.4% of outstanding) were tendered; remaining shares converted at the same price.
  • EMPAVELI and SYFOVRE generated $689 million in combined net product revenue in 2025.
  • The acquisition is expected to be accretive to Biogen's non-GAAP diluted EPS in 2027 and materially increase non-GAAP EPS CAGR through the end of the decade.
  • Apellis brings established nephrology commercial infrastructure to support felzartamab launch, with first Phase 3 readout in antibody-mediated rejection expected in H1 2027.

Financial Impact

Total consideration of approximately $4.3 billion in cash plus up to $420 million in CVRs based on 105.7M shares tendered at $41/share plus $4/share CVR; combined acquired products had $689M in 2025 revenue.

revenueepsdebt

Risk Factors

  • Integration risk: realizing expected synergies and maintaining Apellis product sales momentum.
  • SYFOVRE faces competition from Iveric Bio's avacincaptad pegol (Izervay) in geographic atrophy.
  • CVR payments depend on achieving SYFOVRE net sales thresholds, which may not be met.
  • Felzartamab Phase 3 readout in 2027 is binary and may not succeed.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
56% bullish (43 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3294955

Track record

34 reports on BIIB

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 15 of 16 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
  4. Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  5. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  6. Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
  7. Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
  8. Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
  9. Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
  10. Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
Showing 10 of 34

US Market Status

Market Closed · Opens Wed (11h 44m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026